XOLAIR®

(Omalizumab)

Documentation

Patented
Approved 2003
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: IgE-Fc
Indication Category: Autoimmunity

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA